Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.68 |
| ▸ | GAA | P10253 | 5/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.65 |
| ▸ | GFER | P55789 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | APP | P05067 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | SNCA | P37840 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29824523 | 1.00 | MAPT (0.68) | MAPTGAAALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL6652827 | 0.88 | MAPK13 (0.73) | MAPTGAAALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL1921457 | 0.86 | ALDH1A1 (0.55) | MAPTGAAALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL6290887 | 0.86 | MAPT (0.59) | MAPTGAAALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL4607773 | 0.84 | MAPT (0.86) | MAPTGAAALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL28465275 | 0.84 | MAPT (0.76) | MAPTGAAALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL14214726 | 0.82 | KDM4E (0.50) | MAPTGAAALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL16747849 | 0.82 | SCN5A (0.57) | MAPTGAAALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL11390047 | 0.81 | ALDH1A1 (0.81) | MAPTGAAALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL15875871 | 0.81 | MAPT (0.65) | MAPTGAAALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| EP-4081202-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-115232148-A | Tetracyclic skeleton photosensitizer based on quinoxaline and preparation method and application thereof | 南开大学 | 2022-10-25 | — | — | CN | disclosed |
| CN-115103670-A | Transcription Enhancement Associated Domain (TEAD) transcription factor inhibitors and uses thereof | 达纳-法伯癌症研究所股份有限公司 | 2022-09-23 | — | — | CN | disclosed |
| WO-2021133896-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021133896-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| US-8785002-B1 | High-energy triplet host materials, luminescent layer comprising the same, and organic electroluminescent device comprising the luminescent layer | BOWLING GREEN STATE UNIVERSITY (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785002-B1 | High-energy triplet host materials, luminescent layer comprising the same, and organic electroluminescent device comprising the luminescent layer | BOWLING GREEN STATE UNIVERSITY (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785002-B1 | High-energy triplet host materials, luminescent layer comprising the same, and organic electroluminescent device comprising the luminescent layer | BOWLING GREEN STATE UNIVERSITY (US) | 2014-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | MAPT 516/4885GAA 3205/4885ALDH1A1 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.